Delcath's Liver-Directed Therapy Shows Survival Gains in Uveal Melanoma Trial

Event summary

  • Delcath's CHOPIN Phase 2 trial results published in The Lancet Oncology on March 3, 2026, showing superior survival outcomes for metastatic uveal melanoma patients.
  • Combination of percutaneous hepatic perfusion (PHP) with ipilimumab and nivolumab tripled 1-year progression-free survival (54.7% vs 15.8%) and nearly doubled 2-year overall survival (49.6% vs 22.1%).
  • Objective response rate reached 76.3% in the combination arm compared to 39.5% in the PHP-alone arm.
  • Grade 3 or higher adverse events occurred in 82% of combination arm patients versus 41% in the PHP-alone arm.

The big picture

The CHOPIN trial results position Delcath's PHP technology as a potential game-changer for liver-directed oncology, particularly in combination with immunotherapy. This represents a strategic shift in treating metastatic uveal melanoma, where liver metastases have historically driven poor outcomes. The results may accelerate adoption of Delcath's HEPZATO KIT and CHEMOSAT system in specialized oncology centers, though commercialization will depend on reimbursement dynamics and physician training.

What we're watching

Regulatory Pathway
Whether the FDA will expand HEPZATO KIT's approved indications based on these results.
Commercial Adoption
The pace at which treating physicians adopt this combination therapy for liver-dominant cancers.
Clinical Expansion
How quickly Delcath can initiate trials exploring this approach in other liver-dominant cancers.